Stabilitech
Stabilitech Biopharma is applying its patented THERM-SB platform, for the thermo-stabilisation of viruses, vaccines, proteins and biopharmaceuticals, in the development of various technologies including the OraPro™ oral delivery system for biopharmaceuticals and vaccines.
Stabilitech Biopharma is applying its patented THERM-SB platform, for the thermo-stabilisation of viruses, vaccines, proteins and biopharmaceuticals, in the development of various technologies including the OraPro™ oral delivery system for biopharmaceuticals and vaccines, which:
- enables oral administration of non-replicating vector
- enables repeat administration with the same vector carrying the same or new payload
- enables transient biopharmaceutical production induced within the human/patient gut
- is suitable for vaccines, therapeutic proteins, enzyme replacement, etc
- forms a thermally stable oral capsule
- allows for the re-use of a vector for new developments / enables re-use of large parts of the regulatory dossier
Therm-SB is a formulation of simple sugars and non-toxic small molecules in discrete concentrations and ratios that are mixed with the vaccine during the fill-finish process.
The company has partnerships with several pharma companies including GSK and it seeks additional partnerships for the development of products based on its THERM-SB platform and the OraPro™ technology.
